HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Clinical trials for HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in shrinking breast tumors before surgery
Disease control OngoingThis study tests two drugs, olaparib and pembrolizumab, given before standard surgery for people with triple-negative or hormone receptor-positive HER2-negative breast cancer who have specific gene mutations. The goal is to see if the combination can shrink tumors enough to impro…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Could a drug combo keep High-Risk breast cancer from coming back?
Disease control OngoingThis phase 3 trial tested whether adding the drug everolimus to standard hormone therapy helps prevent breast cancer from returning in nearly 2,000 patients with high-risk, hormone receptor-positive, HER2-negative breast cancer. Participants received either hormone therapy plus e…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug combo shows promise in slowing breast cancer growth
Disease control OngoingThis phase 3 trial tests whether adding abemaciclib to standard hormone therapy (anastrozole or letrozole) can slow cancer growth in postmenopausal women with HR+ HER2- breast cancer that has spread or returned. About 493 women participated, receiving either the drug combination …
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Two-Drug cocktail shows promise for tough cancers
Disease control OngoingThis early-phase study tests whether combining two drugs, abemaciclib and pembrolizumab, is safe and effective for people with advanced non-small cell lung cancer or a certain type of breast cancer. About 100 participants with stage IV disease will receive the combination. The go…
Matched conditions: HORMONE RECEPTOR-POSITIVE/HER2 NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC